Item 1. Financial Statements.
PRAXIS PRECISION MEDICINES, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)
(Amounts in thousands, except share and per share data)
| | | | | | | | | | | |
| March 31, 2022 | | December 31, 2021 |
Assets | | | |
Current assets: | | | |
Cash and cash equivalents | $ | 77,854 | | | $ | 138,704 | |
Marketable securities | 144,662 | | | 137,207 | |
Prepaid expenses and other current assets | 11,957 | | | 11,498 | |
Total current assets | 234,473 | | | 287,409 | |
Property and equipment, net | 1,142 | | | 1,213 | |
Operating lease right-of-use assets | 3,473 | | | 3,653 | |
Other non-current assets | 416 | | | 472 | |
Total assets | $ | 239,504 | | | $ | 292,747 | |
Liabilities and stockholders’ equity | | | |
Current liabilities: | | | |
Accounts payable | $ | 13,269 | | | $ | 10,780 | |
Accrued expenses | 30,929 | | | 26,844 | |
Operating lease liabilities | 1,025 | | | 810 | |
Total current liabilities | 45,223 | | | 38,434 | |
Long-term liabilities: | | | |
Non-current portion of operating lease liabilities | 3,259 | | | 3,501 | |
Total liabilities | 48,482 | | | 41,935 | |
Commitments and contingencies (Note 6) | | | |
Stockholders’ equity: | | | |
Preferred stock, $0.0001 par value; 10,000,000 shares authorized and no shares issued or outstanding as of March 31, 2022 and December 31, 2021 | — | | | — | |
Common stock, $0.0001 par value; 150,000,000 shares authorized; 45,506,482 shares issued and outstanding as of March 31, 2022, and 45,300,514 shares issued and outstanding as of December 31, 2021 | 5 | | | 5 | |
Additional paid-in capital | 576,955 | | | 567,598 | |
Accumulated other comprehensive loss | (606) | | | (176) | |
Accumulated deficit | (385,332) | | | (316,615) | |
Total stockholders’ equity | 191,022 | | | 250,812 | |
Total liabilities and stockholders’ equity | $ | 239,504 | | | $ | 292,747 | |
The accompanying notes are an integral part of these condensed consolidated financial statements.
PRAXIS PRECISION MEDICINES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
(Amounts in thousands, except share and per share data)
| | | | | | | | | | | |
| Three Months Ended March 31, |
| 2022 | | 2021 |
Operating expenses: | | | |
Research and development | $ | 52,652 | | | $ | 17,929 | |
General and administrative | 16,197 | | | 9,490 | |
Total operating expenses | 68,849 | | | 27,419 | |
Loss from operations | (68,849) | | | (27,419) | |
Other income: | | | |
Other income, net | 132 | | | 46 | |
Total other income | 132 | | | 46 | |
Net loss | $ | (68,717) | | | $ | (27,373) | |
Net loss per share attributable to common stockholders, basic and diluted | $ | (1.51) | | | $ | (0.71) | |
Weighted average common shares outstanding, basic and diluted | 45,455,179 | | | 38,470,710 | |
The accompanying notes are an integral part of these condensed consolidated financial statements.
PRAXIS PRECISION MEDICINES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
(Unaudited)
(Amounts in thousands)
| | | | | | | | | | | |
| Three Months Ended March 31, |
| 2022 | | 2021 |
Net loss | $ | (68,717) | | | $ | (27,373) | |
Net unrealized losses on marketable securities, net of tax | (430) | | | (86) | |
Comprehensive loss | $ | (69,147) | | | $ | (27,459) | |
The accompanying notes are an integral part of these condensed consolidated financial statements.
PRAXIS PRECISION MEDICINES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(Unaudited)
(Amounts in thousands, except share data)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Common Stock | | Additional Paid-In Capital | | Accumulated Deficit | | Accumulated Other Comprehensive Loss | | Total Stockholders’ Equity |
| Shares | | Amount | | |
Balance at December 31, 2021 | 45,300,514 | | | $ | 5 | | | $ | 567,598 | | | $ | (316,615) | | | $ | (176) | | | $ | 250,812 | |
Stock-based compensation expense | — | | | — | | | 7,886 | | | — | | | — | | | 7,886 | |
Issuance of common stock from at-the-market public offerings, net of issuance costs | 70,410 | | | — | | | 1,368 | | | — | | | — | | | 1,368 | |
Vesting of restricted stock units | 81,130 | | | — | | | — | | | — | | | — | | | — | |
Shares withheld for taxes for vesting of restricted stock units | (17,850) | | | — | | | (230) | | | — | | | — | | | (230) | |
Issuance of common stock upon exercise of stock options | 72,278 | | | — | | | 333 | | | — | | | — | | | 333 | |
Change in unrealized loss on marketable securities, net of tax | — | | | — | | | — | | | — | | | (430) | | | (430) | |
Net loss | — | | | — | | | — | | | (68,717) | | | — | | | (68,717) | |
Balance at March 31, 2022 | 45,506,482 | | | $ | 5 | | | $ | 576,955 | | | $ | (385,332) | | | $ | (606) | | | $ | 191,022 | |
The accompanying notes are an integral part of these condensed consolidated financial statements.
PRAXIS PRECISION MEDICINES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (continued)
(Unaudited)
(Amounts in thousands, except share data)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Common Stock | | Additional Paid-In Capital | | Accumulated Deficit | | Accumulated Other Comprehensive Loss | | Total Stockholders’ Equity |
| Shares | | Amount | | |
Balance at December 31, 2020 | 38,268,543 | | | $ | 4 | | | $ | 437,007 | | | $ | (149,554) | | | $ | — | | | $ | 287,457 | |
Stock-based compensation expense | — | | | — | | | 4,666 | | | — | | | — | | | 4,666 | |
Issuance of common stock upon exercise of stock options | 352,506 | | | — | | | 851 | | | — | | | — | | | 851 | |
Change in unrealized loss on marketable securities, net of tax | — | | | — | | | — | | | — | | | (86) | | | (86) | |
Net loss | — | | | — | | | — | | | (27,373) | | | — | | | (27,373) | |
Balance at March 31, 2021 | 38,621,049 | | | $ | 4 | | | $ | 442,524 | | | $ | (176,927) | | | $ | (86) | | | $ | 265,515 | |
The accompanying notes are an integral part of these condensed consolidated financial statements.
PRAXIS PRECISION MEDICINES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
(Amounts in thousands)
| | | | | | | | | | | |
| Three Months Ended March 31, |
| 2022 | | 2021 |
Cash flows from operating activities: | | | |
Net loss | $ | (68,717) | | | $ | (27,373) | |
Adjustments to reconcile net loss to net cash used in operating activities: | | | |
Depreciation expense | 93 | | | 23 | |
Stock-based compensation expense | 7,886 | | | 4,666 | |
Non-cash operating lease expense | 180 | | | 183 | |
Amortization of premiums and discounts on marketable securities, net | 375 | | | 261 | |
Changes in operating assets and liabilities: | | | |
Prepaid expenses and other current assets | (1,061) | | | (2,035) | |
Accounts payable | 2,489 | | | 2,208 | |
Accrued expenses | 4,616 | | | (3,477) | |
Operating lease liabilities | (26) | | | (185) | |
Other | 56 | | | 7 | |
Net cash used in operating activities | (54,109) | | | (25,722) | |
Cash flows from investing activities: | | | |
Purchases of property and equipment | (289) | | | (4) | |
Purchases of marketable securities | (83,022) | | | (140,006) | |
Maturities of marketable securities | 74,761 | | | — | |
Net cash used in investing activities | (8,550) | | | (140,010) | |
Cash flows from financing activities: | | | |
Proceeds from at-the-market offerings, net of issuance costs | 1,368 | | | — | |
Payment of issuance costs for at-the-market offerings and initial public offering | (262) | | | (575) | |
Payments of tax withholdings related to vesting of restricted stock units | (230) | | | — | |
Proceeds from exercise of options to purchase common stock | 333 | | | 851 | |
Net cash provided by financing activities | 1,209 | | | 276 | |
Decrease in cash, cash equivalents and restricted cash | (61,450) | | | (165,456) | |
Cash, cash equivalents and restricted cash, beginning of period | 139,720 | | | 297,208 | |
Cash, cash equivalents and restricted cash, end of period | $ | 78,270 | | | $ | 131,752 | |
Reconciliation of cash, cash equivalents and restricted cash: | | | |
Cash and cash equivalents | 77,854 | | | 131,152 | |
Restricted cash | 416 | | | 600 | |
Total cash, cash equivalents and restricted cash | $ | 78,270 | | | $ | 131,752 | |
Supplemental disclosures of non-cash activities: | | | |
Purchases of property and equipment included in accrued expenses and accounts payable | $ | — | | | $ | 51 | |
The accompanying notes are an integral part of these condensed consolidated financial statements.
PRAXIS PRECISION MEDICINES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
1. Nature of the Business
Praxis Precision Medicines, Inc. (“Praxis” or the “Company”) is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system ("CNS") disorders characterized by neuronal excitation-inhibition imbalance. Normal brain function requires a delicate balance of excitation and inhibition in neuronal circuits, which, when dysregulated, can lead to abnormal function and disease. The Company is applying insights from genetic epilepsies to both rare and more prevalent neurological and psychiatric disorders, using its understanding of shared biological targets and circuits in the brain. The Company applies a deliberate and pragmatic precision approach, leveraging a suite of translational tools including novel transgenic and predictive translational animal models and electrophysiology markers, to enable an efficient path to proof-of-concept in patients. Through this approach, the Company has established a broad CNS portfolio with multiple programs, including product candidates across psychiatric disorders, movement disorders and epilepsy, with three clinical-stage product candidates. Each of the Company's clinical-stage product candidates is advancing in more than one indication and the Company anticipates expansion into additional indications. The Company expects multiple topline readouts from its clinical-stage programs and anticipates the launch of two additional clinical development programs in 2022. In addition, the Company has established a robust pipeline of preclinical stage programs through internal research and in-licensing.
Praxis was incorporated in 2015 and commenced operations in 2016. The Company has funded its operations primarily with proceeds from the issuance of redeemable convertible preferred stock and from the sale of common stock through an initial public offering, a follow-on public offering and at-the-market offerings under its shelf registration statement. From inception through March 31, 2022, the Company raised $517.8 million in aggregate cash proceeds from these transactions, net of issuance costs.
The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including but not limited to, risks associated with completing preclinical studies and clinical trials, receiving regulatory approvals for product candidates, development by competitors of new biopharmaceutical products, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Programs currently under development will require significant additional research and development efforts, including preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will realize revenue from product sales.
Liquidity
In accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (Subtopic 205-40), the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that these condensed consolidated financial statements are issued.
The Company has incurred recurring losses since its inception, including a net loss of $68.7 million for the three months ended March 31, 2022. In addition, as of March 31, 2022, the Company had an accumulated deficit of $385.3 million. The Company expects to continue to generate operating losses for the foreseeable future.
The Company expects that its cash, cash equivalents and marketable securities as of March 31, 2022 of $222.5 million will be sufficient to fund the operating expenditures and capital expenditure requirements necessary to advance its research efforts and clinical trials for at least one year from the date of issuance of these condensed consolidated financial statements. The future viability of the Company is dependent on its ability to raise additional capital to finance its operations. The Company’s inability to raise capital as and when needed could have a negative impact on its financial condition and ability to pursue its business strategies. There can be no assurance that the
current operating plan will be achieved or that additional funding will be available on terms acceptable to the Company, or at all.
2. Summary of Significant Accounting Policies
Basis of Presentation
The accompanying condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (“ASC”) and ASUs of the FASB.
The significant accounting policies used in preparation of these condensed consolidated financial statements for the three months ended March 31, 2022 are consistent with those discussed in Note 2 to the consolidated financial statements included in the Company's 2021 Annual Report on Form 10-K, other than as noted below.
Unaudited Interim Condensed Consolidated Financial Information
The accompanying condensed consolidated balance sheet as of March 31, 2022, the condensed consolidated statements of operations for the three months ended March 31, 2022 and 2021, the condensed consolidated statements of comprehensive loss for the three months ended March 31, 2022 and 2021, the condensed consolidated statements of cash flows for the three months ended March 31, 2022 and 2021 and the condensed consolidated statements of stockholders’ equity for the three months ended March 31, 2022 and 2021 are unaudited. The unaudited interim financial statements have been prepared on the same basis as the audited annual consolidated financial statements, and in the opinion of management reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the Company’s financial position as of March 31, 2022, the results of its operations for the three months ended March 31, 2022 and 2021 and its cash flows for the three months ended March 31, 2022 and 2021. Financial statement disclosures for the three months ended March 31, 2022 and 2021 are condensed and do not include all disclosures required for an annual set of financial statements in accordance with GAAP.
The results for the three months ended March 31, 2022 are not necessarily indicative of results to be expected for the year ended December 31, 2022, any other interim periods, or any future year or period.
Use of Estimates
The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, accrued and prepaid research and development expenses, stock-based compensation expense and the recoverability of the Company’s net deferred tax assets and related valuation allowance. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ materially from those estimates.
Recently Issued Accounting Pronouncements
The Company does not expect any recently issued accounting pronouncements to have a material impact on its financial statements.
3. Marketable Securities
The following is a summary of the Company's investment portfolio as of March 31, 2022 and December 31, 2021 (in thousands). | | | | | | | | | | | | | | | | | | | | | | | |
| As of March 31, 2022 |
| | | Gross Unrealized | | Estimated |
| Cost | | Gains | Losses | | Fair Value |
Available-for-sale securities: | | | | | | | |
Corporate debt securities | $ | 54,259 | | | $ | — | | | $ | (438) | | | $ | 53,821 | |
Debt securities issued by U.S. government agencies | 46,073 | | | 2 | | | (70) | | | 46,005 | |
Commercial paper | 32,907 | | | — | | | — | | | 32,907 | |
Total securities with a maturity of one year or less | $ | 133,239 | | | $ | 2 | | | $ | (508) | | | $ | 132,733 | |
| | | | | | | |
Corporate debt securities | 12,029 | | | — | | | (100) | | | 11,929 | |
Total securities with a maturity of one to two years | $ | 12,029 | | | $ | — | | | $ | (100) | | | $ | 11,929 | |
Total available-for-sale securities | $ | 145,268 | | | $ | 2 | | | $ | (608) | | | $ | 144,662 | |
| | | | | | | | | | | | | | | | | | | | | | | |
| As of December 31, 2021 |
| | | Gross Unrealized | | Estimated |
| Cost | | Gains | Losses | | Fair Value |
Available-for-sale securities: | | | | | | | |
Corporate debt securities | $ | 52,214 | | | $ | — | | | $ | (31) | | | $ | 52,183 | |
Commercial paper | 34,993 | | | — | | | — | | | 34,993 | |
Debt securities issued by U.S. government agencies | 12,111 | | | — | | | (8) | | | 12,103 | |
Other debt securities | 6,398 | | | 1 | | | — | | | 6,399 | |
Total securities with a maturity of one year or less | $ | 105,716 | | | $ | 1 | | | $ | (39) | | | $ | 105,678 | |
| | | | | | | |
Corporate debt securities | 31,667 | | | — | | | (138) | | | 31,529 | |
Total securities with a maturity of one to two years | $ | 31,667 | | | $ | — | | | $ | (138) | | | $ | 31,529 | |
Total available-for-sale securities | $ | 137,383 | | | $ | 1 | | | $ | (177) | | | $ | 137,207 | |
As of March 31, 2022, the Company had 15 securities with a total fair market value of $90.8 million in an unrealized loss position. As of December 31, 2021, the Company had 14 securities with a total fair market value of $95.8 million in an unrealized loss position. The Company believes that any unrealized losses associated with the decline in value of its securities is temporary and primarily related to the change in market interest rates since purchase, and believes that it is more likely than not that it will be able to hold its debt securities to maturity. Therefore, the Company anticipates a full recovery of the amortized cost basis of its debt securities at maturity and an allowance was not recognized.
Securities are evaluated for impairment at the end of each reporting period. The Company did not record any impairment related to its available-for-sale securities during the three months ended March 31, 2022 and 2021.
4. Fair Value Measurements
Fair value is defined as the price that would be received to sell an asset in an orderly transaction between market participants at the measurement date. The Company categorizes financial assets measured at fair value based on a fair value hierarchy. The following fair value hierarchy is used to classify financial assets based on observable inputs and unobservable inputs used to value the financial assets:
•Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical assets;
•Level 2: Quoted prices for similar assets in active markets, quoted prices in markets that are not active, or inputs which are unobservable, either directly or indirectly, for substantially the full term of the asset; or
•Level 3: Prices or valuation techniques that require inputs that are both significant to the valuation of the asset and unobservable.
The following tables present information about the Company’s financial assets measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values as of March 31, 2022 and December 31, 2021 (in thousands):
| | | | | | | | | | | | | | | | | | | | | | | |
| As of March 31, 2022 |
| Level 1 | | Level 2 | | Level 3 | | Total |
Assets: | | | | | | | |
Cash equivalents: | | | | | | | |
Money market funds | $ | 44,165 | | | $ | — | | | $ | — | | | $ | 44,165 | |
Marketable securities: | | | | | | | |
Corporate debt securities | — | | | 65,750 | | | — | | | 65,750 | |
Debt securities issued by U.S. government agencies | 46,005 | | | — | | | — | | | 46,005 | |
Commercial paper | — | | | 32,907 | | | — | | | 32,907 | |
| $ | 90,170 | | | $ | 98,657 | | | $ | — | | | $ | 188,827 | |
| | | | | | | | | | | | | | | | | | | | | | | |
| As of December 31, 2021 |
| Level 1 | | Level 2 | | Level 3 | | Total |
Assets: | | | | | | | |
Cash equivalents: | | | | | | | |
Money market funds | $ | 131,372 | | | $ | — | | | $ | — | | | $ | 131,372 | |
Marketable securities: | | | | | | | |
Corporate debt securities | — | | | 83,712 | | | — | | | 83,712 | |
Commercial paper | — | | | 34,993 | | | — | | | 34,993 | |
Debt securities issued by U.S. government agencies | 12,103 | | | — | | | — | | | 12,103 | |
Other debt securities | — | | | 6,399 | | | — | | | 6,399 | |
| $ | 143,475 | | | $ | 125,104 | | | $ | — | | | $ | 268,579 | |
5. Accrued Expenses
Accrued expenses consisted of the following (in thousands):
| | | | | | | | | | | |
| March 31, 2022 | | December 31, 2021 |
Accrued external research and development expenses | $ | 26,092 | | | $ | 17,763 | |
Accrued personnel-related expenses | 2,341 | | | 7,180 | |
Accrued other | 2,496 | | | 1,901 | |
Total accrued expenses | $ | 30,929 | | | $ | 26,844 | |
6. Commitments and Contingencies
In May 2021, the Company entered into a sublease agreement for office space located in Boston, Massachusetts that expires on January 31, 2026, with no option to renew or terminate early. The base rent increases by approximately 2% annually. The Company issued a letter of credit to the landlord related to the security deposit, secured by restricted cash, which is reflected within other non-current assets on the accompanying condensed consolidated balance sheets as of March 31, 2022 and December 31, 2021. This lease qualifies as an operating lease.
7. Common Stock and Preferred Stock
Common Stock
As of March 31, 2022 and December 31, 2021, the authorized capital stock of the Company included 150,000,000 shares of common stock, $0.0001 par value.
As of March 31, 2022 and December 31, 2021, the Company did not hold any treasury shares.
Shares Reserved for Future Issuance
The Company has reserved the following shares of common stock for future issuance:
| | | | | | | | | | | |
| March 31, 2022 | | December 31, 2021 |
Shares reserved for exercise of outstanding stock options | 7,862,576 | | | 6,468,501 | |
Shares reserved for future awards under the 2020 Stock Option and Incentive Plan | 3,014,484 | | | 2,667,780 | |
Shares reserved for future awards under the 2020 Employee Stock Purchase Plan | 981,306 | | | 654,204 | |
Shares reserved for vesting of restricted stock units | 840,277 | | | 440,079 | |
Total shares of authorized common stock reserved for future issuance | 12,698,643 | | | 10,230,564 | |
Preferred Stock
As of March 31, 2022 and December 31, 2021, the authorized capital stock of the Company included 10,000,000 shares of undesignated preferred stock, $0.0001 par value.
8. Stock-Based Compensation
2020 Stock Option and Incentive Plan
The total number of shares of common stock authorized for issuance under the 2020 Stock Option and Incentive Plan (the "2020 Plan”) as of March 31, 2022 and December 31, 2021 was 7,449,480 shares and 5,184,455 shares, respectively.
2017 Stock Incentive Plan
The total number of shares of common stock authorized for issuance under the 2017 Stock Incentive Plan (the "2017 Plan”) as of March 31, 2022 and December 31, 2021 was 5,937,763 shares. Any authorization to issue new options under the 2017 Plan was cancelled upon the effectiveness of the 2020 Plan and no further awards will be granted under the 2017 Plan.
2020 Employee Stock Purchase Plan
The total number of shares of common stock authorized for issuance under the 2020 Employee Stock Purchase Plan (the "2020 ESPP”) as of March 31, 2022 and December 31, 2021 was 981,306 shares and 654,204 shares, respectively.
Restricted Stock Units
The following table summarizes the Company’s restricted stock unit activity:
| | | | | | | | | | | |
| Shares | | Weighted Average Grant Date Fair Value |
Unvested as of December 31, 2021 | 440,079 | | | $ | 41.86 | |
Issued | 520,328 | | | 17.33 | |
Vested | (81,130) | | | 51.78 | |
Forfeited | (39,000) | | | 23.43 | |
Unvested as of March 31, 2022 | 840,277 | | | $ | 26.57 | |
As of March 31, 2022, total unrecognized compensation cost related to unvested restricted stock units was $20.9 million, which is expected to be recognized over a weighted-average period of 3.32 years.
Stock Options
The following table summarizes the Company’s stock option activity:
| | | | | | | | | | | | | | | | | | | | | | | |
| Number of Shares | | Weighted Average Exercise Price per Share | | Weighted Average Remaining Contractual Term | | Aggregate Intrinsic Value |
| | | | | (In years) | | (In thousands) |
Outstanding as of December 31, 2021 | 6,468,501 | | | $ | 16.92 | | | | | |
Granted | 1,631,898 | | | 17.63 | | | | | |
Exercised | (72,278) | | | 4.56 | | | | | $ | 739 | |
Cancelled or Forfeited | (165,545) | | | 21.50 | | | | | |
Outstanding as of March 31, 2022 | 7,862,576 | | | $ | 17.10 | | | 8.68 | | $ | 14,030 | |
Exercisable as of March 31, 2022 | 2,496,400 | | | $ | 13.35 | | | 8.03 | | $ | 8,116 | |
Vested and expected to vest as of March 31, 2022 | 7,862,576 | | | $ | 17.10 | | | 8.68 | | $ | 14,030 | |
The aggregate intrinsic value of stock options outstanding, exercisable, and vested and expected to vest is calculated as the difference between the exercise price of the underlying stock options and the estimated fair value of the Company’s common stock for those stock options that had exercise prices lower than the estimated fair value of the Company’s common stock at March 31, 2022. The aggregate intrinsic value of stock options exercised is calculated as the difference between the exercise price of the underlying stock options and the estimated fair value of the Company’s common stock on the date of exercise for those stock options that had exercise prices lower than the estimated fair value of the Company’s common stock on the exercise date.
Stock Option Valuation
The weighted-average assumptions that the Company used in the Black-Scholes option pricing model to determine the grant-date fair value of stock options granted to employees and non-employees on the date of grant were as follows for the three months ended March 31, 2022:
| | | | | | | |
| Three Months Ended March 31, | | |
| 2022 | | |
Risk-free interest rate | 1.61 | % | | |
Expected term (in years) | 6.15 | | |
Expected volatility | 90.36 | % | | |
Expected dividend yield | — | % | | |
Weighted average grant-date fair value per share | $ | 13.20 | | | |
As of March 31, 2022, total unrecognized compensation cost related to unvested stock options was $70.0 million, which is expected to be recognized over a weighted-average period of 2.76 years.
Stock-Based Compensation
Stock-based compensation expense was allocated as follows (in thousands):
| | | | | | | | | | | |
| Three Months Ended March 31, |
| 2022 | | 2021 |
Research and development | $ | 3,214 | | | $ | 2,318 | |
General and administrative | 4,672 | | | 2,348 | |
Total stock-based compensation expense | $ | 7,886 | | | $ | 4,666 | |
9. Net Loss per Share
The following potential shares of common stock, presented based on amounts outstanding at each period end, were excluded from the calculation of diluted net loss per share for the periods indicated because including them would have been anti-dilutive:
| | | | | | | | | | | |
| Three Months Ended March 31, |
| 2022 | | 2021 |
Outstanding stock options | 7,862,576 | | | 6,648,367 | |
Unvested restricted stock units | 840,277 | | | 328,363 | |
Potential shares issuable under the 2020 ESPP | 30,341 | | | — | |
| 8,733,194 | | | 6,976,730 | |
10. Related Party Transactions
On September 11, 2019, the Company entered into a Cooperation and License Agreement (the “License Agreement”) with RogCon Inc. (“RogCon”). Under the License Agreement, RogCon granted to the Company an exclusive, worldwide license under RogCon’s intellectual property to research, develop and commercialize products for the treatment of all forms of epilepsy and/or neurodevelopmental disorders in each case caused by any mutation of the SCN2A gene. Pursuant to the terms of the License Agreement, the Company will conduct, at its own cost and expense, the research and development activities assigned to it under the associated research plan. In addition, the Company is responsible for reimbursing RogCon for any costs associated with research and development activities RogCon performs at the request of the Company. One of the founders of RogCon became the Company’s General Counsel in June 2020. The Company continues to reimburse RogCon for its out-of-pocket costs incurred for activities performed under the License Agreement. Expenses incurred during all periods presented were not material. As of March 31, 2022, the Company had accrued expenses of $0.3 million due to RogCon under the License Agreement.
11. Subsequent Events
The Company considers events or transactions that occur after the balance sheet date but prior to the issuance of the condensed consolidated financial statements to provide additional evidence for certain estimates or to identify matters that require additional disclosure. The Company has concluded that no subsequent events have occurred that require disclosure.
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
You should read the following discussion and analysis of our financial condition and results of operations together with our condensed consolidated financial statements and related notes appearing elsewhere in this Quarterly Report on Form 10-Q and the audited financial information and the notes thereto included in our Annual Report on Form 10-K, which was filed with the Securities and Exchange Commission (the "SEC") on February 28, 2022. Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report on Form 10-Q, including information with respect to our plans and strategy for our business and related financing, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in the “Risk Factors” section of our Annual Report on Form 10-K for the year ended December 31, 2021 and set forth in the "Risk Factors" section of this Quarterly Report on Form 10-Q, our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.
Overview
We are a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system, or CNS, disorders characterized by neuronal excitation-inhibition imbalance. Normal brain function requires a delicate balance of excitation and inhibition in neuronal circuits, which, when dysregulated, can lead to abnormal function and disease. We are applying insights from genetic epilepsies to both rare and more prevalent neurological and psychiatric disorders, using our understanding of shared biological targets and circuits in the brain. We apply a deliberate and pragmatic precision approach, leveraging a suite of translational tools including novel transgenic and predictive translational animal models and electrophysiology markers, to enable an efficient path to proof-of-concept in patients. Through this approach, we have established a broad CNS portfolio with multiple programs, including product candidates across psychiatric disorders, movement disorders and epilepsy, with three clinical-stage product candidates. Each of our clinical-stage product candidates is advancing in more than one indication and we anticipate expansion into additional indications. We expect multiple topline readouts from our clinical-stage programs and anticipate the launch of two additional clinical development programs this year. In addition, we have established a robust pipeline of preclinical stage programs through internal research and in-licensing.
Our broad portfolio of CNS programs is currently structured by therapeutic focus in three franchises – Psychiatry, Movement Disorders and Epilepsy. Within our Psychiatry franchise, our most advanced clinical candidate, PRAX-114, is being developed for the treatment of a broad range of patients suffering from major depressive disorder, or MDD, and post-traumatic stress disorder, or PTSD. We have completed the Aria Study, a Phase 2/3, placebo-controlled study evaluating PRAX-114 for monotherapy treatment of MDD, and expect to report topline results in June 2022. Following topline results from the Aria Study, we intend to engage with the U.S. Food and Drug Administration, or FDA, for an end-of-Phase 2 meeting and subsequently initiate a Phase 3, placebo-controlled study in the fourth quarter of 2022. We also expect to report topline results from the Acapella Study, a Phase 2, placebo-controlled, dose-ranging study evaluating PRAX-114 for treatment of MDD, in the third quarter of 2022. In addition, we expect to report topline results from a Phase 2, placebo-controlled study evaluating PRAX-114 for the treatment of PTSD in the second half of 2022.
Within our Movement Disorders franchise, our second clinical candidate, PRAX-944, is being developed for the treatment of Essential Tremor, or ET, and Parkinson's Disease, or PD. In May 2022, we reported positive topline results from the second cohort of our Phase 2a trial evaluating PRAX-944 for the treatment of ET. We expect to report topline results from the Phase 2b placebo-controlled Essential1 Study for daytime treatment of ET in the second half of 2022. Following the topline results from the second cohort, Part B, of the Phase 2a study of PRAX-944 for the treatment of ET, we intend to change the primary endpoint of the Essential1 Study from safety to efficacy. We also initiated a Phase 2, placebo-controlled, crossover study to evaluate the safety, pharmacokinetics, or PK, and efficacy of daytime dosing of PRAX-114 for the treatment of ET in the first quarter of 2022 and expect to report topline results in the second half of 2022. In addition, the FDA cleared the Investigational New Drug, or IND, submission for a Phase 2 study of PRAX-944 for the treatment of PD. We intend to initiate a Phase 2, placebo-controlled trial to evaluate the safety, PK and efficacy of PRAX-944 as a non-dopaminergic treatment for the motor symptoms of PD in the second half of 2022.
Within our Epilepsy franchise, we expect to initiate a Phase 2, placebo-controlled study with our third clinical-stage candidate, PRAX-562, in the second half of 2022 for the treatment of rare pediatric Developmental and Epileptic Encephalopathies. Our most advanced preclinical stage product candidate within our Epilepsy franchise,
PRAX-222, is an antisense oligonucleotide, or ASO, designed to decrease the expression levels of the protein encoded by the gene SCN2A in patients with gain-of-function SCN2A mutations. In April 2022, we announced that we received an email communication from the FDA that our IND application for the first-in-patient study of PRAX-222 was place on clinical hold. The letter detailing the reasons for the hold is expected to be received from the FDA within 30 days of April 28, 2022. We expect to initiate a Phase 1 study with our preclinical candidate, PRAX-628, in the fourth quarter of 2022 and subsequently initiate a Phase 2 study in focal epilepsy in 2023. Our preclinical pipeline also consists of discovery programs in development for KCNT1 related epilepsy, three ASOs targeting SCN2A in patients with loss-of-function mutations, PCDH19 and SYNGAP1, respectively, and three additional discovery programs for undisclosed targets in psychiatry, movement disorders and epilepsy. We plan to declare ASO candidates for PRAX-080 for PCDH19 and PRAX-090 for SYNGAP1 in 2023.
We were incorporated in 2015 and commenced operations in 2016. Since inception, we have devoted substantially all of our resources to developing our preclinical and clinical product candidates, building our intellectual property, or IP, portfolio, business planning, raising capital and providing general and administrative support for these operations. We employ a “virtual” research and development model, relying heavily upon external consultants, collaborators and contract research organizations, or CROs, to conduct our preclinical and clinical activities. Since inception, we have financed our operations primarily with proceeds from the sale and issuance of equity securities.
We are a development stage company and we have not generated any revenue from product sales, and do not expect to do so for several years, if at all. All of our product candidates are still in preclinical and clinical development. Our ability to generate product revenue sufficient to achieve profitability will depend heavily on the successful development and eventual commercialization of one or more of our product candidates, if approved. We have incurred recurring operating losses since inception, including a net loss of $68.7 million for the three months ended March 31, 2022. As of March 31, 2022, we had an accumulated deficit of $385.3 million. We expect to incur significant expenses and operating losses for the foreseeable future as we expand our research and development activities. In addition, our losses from operations may fluctuate significantly from quarter-to-quarter and year-to-year, depending on the timing of our clinical trials and our expenditures on other research and development activities. We anticipate that our expenses will be maintained or increased in connection with our ongoing activities, as we:
•advance our lead product candidates, PRAX-114 and PRAX-944, to late stage clinical trials;
•advance our PRAX-562 product candidate to Phase 2 clinical trial;
•advance our PRAX-222 product candidate to clinical trials;
•advance our preclinical candidates to clinical trials;
•further invest in our pipeline;
•further invest in our manufacturing capabilities;
•seek regulatory approval for our product candidates;
•maintain, expand, protect and defend our IP portfolio;
•acquire or in-license technology;
•take temporary precautionary measures to help minimize the risk of COVID-19 to our employees; and
•increase our headcount to support our development efforts and to expand our clinical development team.
In addition, as we progress toward potential marketing approval for any of our product candidates, we expect to incur significant commercialization expenses related to product manufacturing, marketing, sales and distribution.
As a result, we will need substantial additional funding to support our continuing operations and pursue our growth strategy. Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operations through the sale of equity, debt financings or other capital sources, including potential collaborations with other companies or other strategic transactions. We may be unable to raise additional funds or enter into such other agreements or arrangements when needed on favorable terms, or at all. If we fail to raise capital or enter into such agreements as, and when, needed, we may have to significantly delay, scale back or discontinue the development and commercialization of one or more of our product candidates or delay our pursuit of potential in-licenses or acquisitions.
Because of the numerous risks and uncertainties associated with product development, we are unable to predict the timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability. Even if we are able to generate product sales, we may not become profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce or terminate our operations.
As of March 31, 2022, we had cash, cash equivalents and marketable securities of $222.5 million. We believe that our existing cash, cash equivalents and marketable securities will enable us to fund our operating expenses and capital expenditures into the third quarter of 2023. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect. See “—Liquidity and Capital Resources.”
COVID-19 Business Update
In light of the ongoing COVID-19 pandemic, we continue to experience some disruptions and increased risk in our operations and those third parties upon whom we rely. These include disruptions and risks related to the conduct of our clinical trials and preclinical studies as policies at various clinical sites and federal, state, local and foreign laws, rules and regulations continue to evolve, including quarantines, travel restrictions and redirection of healthcare resources toward pandemic response efforts. The COVID-19 pandemic has impacted the enrollment of some of our ongoing clinical trials, including slower patient enrollment and treatment in some of our clinical studies, the impact of which has varied by clinical study and program, but none of which have significantly impacted our overall clinical trial timelines. While we have experienced limited financial impacts to date, given the global economic slowdown, the overall disruption of global healthcare systems and the other risks and uncertainties associated with the pandemic such as increased inflation, our business, financial condition and results of operations could be materially adversely affected. We continue to closely monitor the COVID-19 pandemic as we evolve our business continuity plans, clinical development plans and response strategy.
Financial Operations Overview
Revenue
We have not generated any revenue since inception and do not expect to generate any revenue from the sale of products for several years, if at all. If our development efforts for our current or future product candidates are successful and result in marketing approval or collaboration or license agreements with third parties, we may generate revenue in the future from a combination of product sales or payments from such collaboration or license agreements.
Operating Expenses
Research and Development Expense
The nature of our business and primary focus of our activities generate a significant amount of research and development costs. Research and development expenses represent costs incurred by us for the following:
•costs to develop our portfolio;
•discovery efforts leading to development candidates;
•clinical development costs for our product candidates; and
•costs to develop our manufacturing technology and infrastructure.
The costs above comprise the following categories:
•personnel-related expenses, including salaries, benefits and stock-based compensation expense;
•expenses incurred under agreements with third parties, such as consultants, investigative sites and CROs, that conduct our preclinical and clinical studies and in-licensing arrangements;
•costs incurred to maintain compliance with regulatory requirements;
•costs incurred with third-party contract development and manufacturing organizations to acquire, develop and manufacture materials for preclinical and clinical studies; and
•depreciation, amortization and other direct and allocated expenses, including rent, insurance and other operating costs, incurred as a result of our research and development activities.
We expense research and development costs as incurred. We recognize external development costs based on an evaluation of the progress to completion of specific tasks using information provided to us by our vendors and our clinical investigative sites. Payments for these activities are based on the terms of the individual agreements, which may differ from the pattern of costs incurred, and are reflected in our consolidated balance sheets as prepaid expenses or accrued expenses. Non-refundable advance payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized, even when there is no alternative future use for the research and development. The capitalized amounts are expensed as the related goods are delivered or the services are performed.
As a company operating in a virtual environment, a significant portion of our research and development costs have been external costs. We track direct external research and development expenses to specific franchises and product candidates upon commencement. Due to the number of ongoing studies and our ability to use resources across several projects, indirect or shared operating costs incurred for our research and development franchises, such as personnel, facility costs and certain consulting costs, are not recorded or maintained on a franchise-specific basis.
The following table reflects our research and development expenses, including direct expenses summarized by major franchise and other exploratory CNS indications and indirect or shared operating costs recognized as research and development expenses during each period presented (in thousands):
| | | | | | | | | | | |
| Three Months Ended March 31, |
| 2022 | | 2021 |
Psychiatry | $ | 14,438 | | | $ | 3,201 | |
Epilepsy | 14,264 | | | 4,926 | |
Movement disorders | 9,104 | | | 1,577 | |
Other exploratory CNS indications | 2,191 | | | 663 | |
Personnel-related (including stock-based compensation) | 11,141 | | | 6,505 | |
Other indirect research and development expenses | 1,514 | | | 1,057 | |
Total research and development expenses | $ | 52,652 | | | $ | 17,929 | |
Research and development activities are central to our business model. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. We expect that our research and development expenses will continue to increase in the foreseeable future as we advance our product candidates through the development phase, and as we continue to discover and develop additional product candidates, build manufacturing capabilities and expand into additional therapeutic areas.
At this time, we cannot reasonably estimate or know the nature, timing and estimated costs of the efforts that will be necessary to complete the development of, and obtain regulatory approval for, any of our product candidates. We are also unable to predict when, if ever, material net cash inflows will commence from sales or licensing of our product candidates. This is due to the numerous risks and uncertainties associated with drug development, including the uncertainty of:
•our ability to add and retain key research and development personnel;
•the timing and progress of preclinical and clinical development activities;
•the number and scope of preclinical and clinical programs we decide to pursue;
•our ability to successfully complete clinical trials with safety, tolerability and efficacy profiles that are satisfactory to the U.S. Food and Drug Administration, or FDA, or any comparable foreign regulatory authority;
•our ability to successfully develop, obtain regulatory approval for, and then successfully commercialize, our product candidates;
•our successful enrollment in and completion of clinical trials;
•the costs associated with the development of any additional product candidates we identify in-house or acquire through collaborations;
•our ability to discover, develop and utilize biomarkers to demonstrate target engagement, pathway engagement and the impact on disease progression of our product candidates;
•our ability to establish and maintain agreements with third-party manufacturers for clinical supply for our clinical trials and commercial manufacturing, if our product candidates are approved;
•the terms and timing of any collaboration, license or other arrangement, including the terms and timing of any milestone payments thereunder;
•our ability to obtain and maintain patent, trade secret and other IP protection and regulatory exclusivity for our product candidates, if approved;
•our receipt of marketing approvals from applicable regulatory authorities;
•our ability to commercialize products, if approved, whether alone or in collaboration with others; and
•the continued acceptable safety profiles of the product candidates following approval.
A change in any of these variables with respect to the development of any of our product candidates would significantly change the costs, timing and viability associated with the development of that product candidate. For example, if the FDA or another regulatory authority were to delay our planned start of clinical trials or require us to conduct clinical trials or other testing beyond those that we currently expect, or if we experience significant delays in enrollment in any of our planned clinical trials, we could be required to expend significant additional financial resources and time to complete our clinical development activities. We may never obtain regulatory approval for any of our product candidates. Drug commercialization will take several years and require significant development costs.
General and Administrative Expense
General and administrative expenses consist primarily of personnel-related costs, including salaries, benefits and stock-based compensation, for personnel in our executive, finance, legal, commercial and administrative functions. General and administrative expenses also include legal fees relating to corporate matters; professional fees for accounting, auditing, tax and administrative consulting services; commercial-related costs to support market assessments and scenario planning; insurance costs; administrative travel expenses; and facility-related expenses, which include direct depreciation costs and allocated expenses for office rent and other operating costs. These costs relate to the operation of the business, unrelated to the research and development function, or any individual franchises or product candidate. Costs to secure and defend our IP are expensed as incurred and are classified as general and administrative expenses.
We anticipate that our general and administrative expenses will increase in the future as we increase our headcount to support the expected growth in our research and development activities and the potential commercialization of our product candidates. We also expect to incur additional IP-related expenses as we file patent applications to protect innovations arising from our research and development activities.
Other Income
Other Income, Net
Other income, net consists of interest income from our cash, cash equivalents and marketable securities and amortization of investment premiums and discounts.
Income Taxes
Since our inception, we have not recorded any U.S. federal or state income tax benefits for the net losses we have incurred in each year or for our earned research and development tax credits due to our uncertainty of realizing a benefit from those items. Income taxes are determined at the applicable tax rates adjusted for non-deductible expenses, research and development tax credits and other permanent differences. Our income tax provision may be significantly affected by changes to our estimates. The income tax benefit (provision) for the three months ended March 31, 2022 and 2021 was not material.
Results of Operations
Comparison of the Three Months Ended March 31, 2022 and 2021
The following table summarizes our consolidated statements of operations for each period presented (in thousands):
| | | | | | | | | | | | | | | | | |
| Three Months Ended March 31, | | Change |
| 2022 | | 2021 | | |
Operating expenses: | | | | | |
Research and development | $ | 52,652 | | | $ | 17,929 | | | $ | 34,723 | |
General and administrative | 16,197 | | | 9,490 | | | 6,707 | |
Total operating expenses | 68,849 | | | 27,419 | | | 41,430 | |
Loss from operations | (68,849) | | | (27,419) | | | (41,430) | |
Total other income: | | | | | |
Other income, net | 132 | | | 46 | | | 86 | |
Total other income | 132 | | | 46 | | | 86 | |
Net loss | $ | (68,717) | | | $ | (27,373) | | | $ | (41,344) | |
Research and Development Expense
The following table summarizes our research and development expenses for each period presented, along with the changes in those items (in thousands):
| | | | | | | | | | | | | | | | | |
| Three Months Ended March 31, | | Change |
| 2022 | | 2021 | | |
Psychiatry | $ | 14,438 | | | $ | 3,201 | | | $ | 11,237 | |
Epilepsy | 14,264 | | | 4,926 | | | 9,338 | |
Movement disorders | 9,104 | | | 1,577 | | | 7,527 | |
Other exploratory CNS indications | 2,191 | | | 663 | | | 1,528 | |
Personnel-related (including stock-based compensation) | 11,141 | | | 6,505 | | | 4,636 | |
Other indirect research and development expenses | 1,514 | | | 1,057 | | | 457 | |
Total research and development expenses | $ | 52,652 | | | $ | 17,929 | | | $ | 34,723 | |
The $34.7 million increase in research and development expenses was primarily attributable to the following:
•$11.2 million increase in expense related to our psychiatry franchise, driven primarily by an increase in clinical-related spend for our PRAX-114 Phase 2/3 Aria and Acapella clinical trials which were initiated in the first quarter and second quarter of 2021, respectively;
•$9.3 million increase in expense related to our epilepsy franchise, driven primarily by an increase in clinical-related spend to support the initiation of our PRAX-562 Phase 2 developmental epileptic encephalopathies clinical trial and our anticipated PRAX-222 seamless clinical trial, an increase in clinical-related spend for our PRAX-562 Phase 1 clinical trial, an increase in preclinical activities for our earlier stage assets, and the payment of a $2.0 million license fee to Ionis Pharmaceuticals, Inc. in January of 2022 upon exercise of our exclusive option to obtain the rights and license to further develop and commercialize PRAX-222;
•$7.5 million increase in expense related to our movement disorders franchise, driven primarily by an increase in clinical-related spend for our PRAX-944 Phase 2 Essential1 clinical trial;
•$4.6 million increase in personnel-related costs due to increased headcount;
•$1.5 million increase in other exploratory CNS indications, driven primarily by clinical-related expenses for a planned Phase 2 trial in rare adult cephalgias which we have determined not to pursue, as well as increased preclinical activities for our earlier stage assets; and
•$0.5 million increase in other indirect research and development expenses, driven primarily by an increase in technology spend and related consulting costs to support our expanding operations.
General and Administrative Expense
The $6.7 million increase in general and administrative expenses was primarily attributable to the following:
•$5.0 million increase in personnel-related costs, driven primarily by increased headcount, including an increase of $2.4 million in stock-based compensation expense; and
•$1.7 million increase in other general and administrative expenses, none of which were individually significant.
Other Income
Other income for the three months ended March 31, 2022 and 2021 was comprised of interest income on our cash, cash equivalents and marketable securities and investment premium and discount amortization.
Liquidity and Capital Resources
Sources of Liquidity
Since our inception, we have incurred significant losses in each period. We have not yet commercialized any of our product candidates, which are in various phases of preclinical and clinical development, and we do not expect to generate revenue from sales of any products for several years, if at all.
To date, we have financed our operations primarily with proceeds from the sale and issuance of equity securities. From inception through March 31, 2022, we have raised $517.8 million in aggregate cash proceeds from such transactions, net of issuance costs. As of March 31, 2022, we had cash, cash equivalents and marketable securities of $222.5 million.
On November 3, 2021, we entered into an Open Market Sale Agreement, or the sales agreement, with Jefferies LLC, or Jefferies, to provide for the offering, issuance and sale of up to an aggregate amount of $125.0 million of common stock from time to time in at-the-market offerings for which Jefferies acts as sales agent. During the three months ended March 31, 2022, we issued and sold 70,410 shares under the sales agreement for aggregate net proceeds of $1.4 million. We have issued and sold a total of 462,407 shares under the sales agreement for aggregate net proceeds of $8.4 million after deducting commissions and offering expenses payable by us.
Historical Cash Flows
The following table provides information regarding our cash flows for each period presented (in thousands):
| | | | | | | | | | | |
| Three Months Ended March 31, |
| 2022 | | 2021 |
Net cash (used in) provided by: | | | |
Operating activities | $ | (54,109) | | | $ | (25,722) | |
Investing activities | (8,550) | | | (140,010) | |
Financing activities | 1,209 | | | 276 | |
Net decrease in cash, cash equivalents and restricted cash | $ | (61,450) | | | $ | (165,456) | |
Operating Activities
Our cash flows from operating activities are greatly influenced by our use of cash for operating expenses and working capital requirements to support our business. We have historically experienced negative cash flows from operating activities as we have invested in developing our portfolio, drug discovery efforts and related infrastructure.
The cash used in operating activities resulted primarily from our net losses adjusted for non-cash charges and changes in operating assets and liabilities, which are primarily the result of increased expenses and timing of vendor payments.
During the three months ended March 31, 2022, net cash used in operating activities of $54.1 million was primarily due to our $68.7 million net loss, partially offset by $8.5 million of non-cash charges primarily related to stock-based compensation, and $6.1 million in changes in operating assets and liabilities primarily related to increases in accounts payable and accrued expenses.
During the three months ended March 31, 2021, net cash used in operating activities of $25.7 million was primarily due to our $27.4 million net loss and $3.5 million in changes in operating assets and liabilities primarily related to a decrease in accrued expenses and prepaid expenses and other current assets, partially offset by $5.1 million of non-cash charges primarily related to stock-based compensation.
Investing Activities
During the three months ended March 31, 2022, net cash used in investing activities of $8.6 million was primarily related to the purchase of marketable securities, partially offset by the maturity of marketable securities.
During the three months ended March 31, 2021, net cash used in investing activities of $140.0 million was primarily related to the purchase of marketable securities.
Financing Activities
During the three months ended March 31, 2022, net cash provided by financing activities of $1.2 million consisted of net proceeds from at-the-market offerings of $1.4 million and net proceeds from the exercise of stock options of $0.3 million partially offset by the payment of issuance costs for our at-the-market offerings and the payment of taxes related to the vesting of restricted stock units.
During the three months ended March 31, 2021, net cash provided by financing activities was not material.
Plan of Operation and Future Funding Requirements
We expect our expenses to increase substantially in connection with our ongoing research and development activities, particularly as we advance the preclinical activities and clinical trials of our product candidates. As a result, we expect to incur substantial operating losses and negative operating cash flows for the foreseeable future. We anticipate that our expenses will increase substantially if and as we:
•advance the clinical development of our clinical-stage product candidates within our psychiatry, movement disorders and epilepsy franchises, respectively;
•advance the development of any additional product candidates;
•conduct research and continue preclinical development of potential product candidates;
•make strategic investments in manufacturing capabilities;
•maintain our IP portfolio and opportunistically acquire complementary IP;
•seek to obtain regulatory approvals for our product candidates;
•potentially establish a sales, marketing and distribution infrastructure and scale-up manufacturing capabilities to commercialize any products for which we may obtain regulatory approval;
•add clinical, scientific, operational, financial and management information systems and personnel, including personnel to support our product development and potential future commercialization efforts and to support our operations as a public company; and
•experience any delays or encounter any issues with any of the above, including but not limited to failed studies, complex results, safety issues or other regulatory challenges.
We are unable to estimate the exact amount of our working capital requirements, but based on our current operating plan, we believe that our existing cash, cash equivalents and marketable securities will enable us to fund
our operating expenses and capital expenditure requirements into the third quarter of 2023. However, we have based this estimate on assumptions that may prove to be wrong and we could exhaust our capital resources sooner than we expect.
Because of the numerous risks and uncertainties associated with product development and potential collaborations with third parties for the development of our product candidates, we may incorrectly estimate the timing and amounts of increased capital outlays and operating expenses associated with completing the research and development of our product candidates. Our funding requirements and timing and amount of our operating expenditures will depend on many factors, including, but not limited to:
•the scope, progress, results and costs of preclinical studies and clinical trials for our franchises and product candidates;
•the number and characteristics of product candidates and technologies that we develop or may in-license;
•the costs and timing of future commercialization activities, including manufacturing, marketing, sales and distribution, for any of our product candidates for which we receive marketing approval;
•the costs necessary to obtain regulatory approvals, if any, for products in the United States and other jurisdictions, and the costs of post-marketing studies that could be required by regulatory authorities in jurisdictions where approval is obtained;
•the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our IP rights and defending any IP-related claims;
•the continuation of our existing licensing arrangements and entry into new collaborations and licensing arrangements;
•the costs we incur in maintaining business operations;
•the costs associated with being a public company;
•the revenue, if any, received from commercial sales of any product candidates for which we receive marketing approval;
•the effect of competing technological and market developments;
•the impact of any business interruptions to our operations or to those of our manufacturers, suppliers or other vendors resulting from the COVID-19 pandemic or similar public health crisis; and
•the extent to which we acquire or invest in businesses, products and technologies, including entering into licensing or collaboration arrangements for product candidates, although we currently have no commitments or agreements to complete any such acquisitions or investments in businesses.
Identifying potential product candidates and conducting preclinical testing and clinical trials is a time consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain marketing approval and achieve product sales. In addition, our product candidates, if approved, may not achieve commercial success. Our commercial revenues, if any, will be derived from sales of products that we do not expect to be commercially available for many years, if ever. Accordingly, we will need to obtain substantial additional funds to achieve our business objectives.
Adequate additional funds may not be available to us on acceptable terms, or at all. We do not currently have any committed external source of funds. Market volatility resulting from the COVID-19 pandemic or other factors could also adversely impact our ability to access capital as and when needed. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of holders of our common stock. Additional debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends and may require the issuance of warrants, which could potentially result in dilution to the holders of our common stock.
If we raise additional funds through collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional
funds through equity or debt financings when needed, we may be required to delay, limit or terminate our product development programs or any future commercialization efforts or grant rights to develop and market product candidates to third parties that we would otherwise prefer to develop and market ourselves.
Critical Accounting Policies and Significant Judgments and Estimates
Our management’s discussion and analysis of our financial condition and results of operations is based on our condensed consolidated financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States. The preparation of these condensed consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, as well as the reported expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.
There have been no changes to our critical accounting policies from those described under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations – Critical Accounting Policies and Significant Judgments and Estimates” included in our Annual Report on Form 10-K filed with the SEC on February 28, 2022.
Recently Issued Accounting Pronouncements
We have reviewed all recently issued standards and have determined that, other than as disclosed in Note 2 to our condensed consolidated financial statements appearing elsewhere in this Quarterly Report on Form 10-Q, such standards will not have a material impact on our condensed consolidated financial statements or do not otherwise apply to our current operations.